Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae155 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Kassem S Faraj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dow Division of Health Services Research, Department of Urology, University of Michigan, MI, USA. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI, NIH.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
The use of androgen biosynthesis and second-generation androgen receptor inhibitors for advanced prostate cancer is increasing. Because these therapies alter the androgen pathway, they have been associated with cardiometabolic and neurocognitive toxicities. Although their safety profiles have been assessed in clinical trials, real-world data are limited.
Methods
A 20% sample of national Medicare claims was used to perform a retrospective cohort study of Medicare beneficiaries with advanced prostate cancer treated with androgen biosynthesis (ie, abiraterone) and second-generation androgen receptor inhibitors between 2012 and 2019. Outcomes were assessed after the first fill of either class of drug for the 12-month period after starting therapy. The primary outcome was a hospital admission or emergency department visit for a cardiometabolic event. Secondary outcomes included neurocognitive events and fractures. Multivariable regression was used to assess the association between the class of drug and occurrence of an adverse event.
Results
There were 3488 (60%) men started on an androgen biosynthesis inhibitor and 2361 (40%) started on an androgen receptor inhibitor for the first time. Cardiometabolic adverse events were more common in men managed with androgen biosynthesis inhibitor (9.2% vs 7.5%, P = .027). No difference between androgen biosynthesis and androgen receptor inhibitors was observed for neurocognitive events (3.3% vs 3.4%, respectively; P = .71) or fractures (4.2% vs 3.6%, respectively; P = .26).
Conclusions
Men with advanced prostate cancer initiating an androgen biosynthesis inhibitor for the first time more commonly had cardiometabolic events than those started on androgen receptor inhibitors. Neurocognitive events and fractures did not differ by drug class.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dow Division of Health Services Research, Department of Urology, University of Michigan, MI, USA.
- Department of Urology, Massachusetts General Hospital, Boston, MA, USA.
- VA Health Services Research & Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
- Division of Nephrology, Department of Internal Medicine, University of Michigan, MI, USA.
ORCID-Profile: Kassem S Faraj
Förderung
- NCI NIH HHS
- NCI
- NIH
Zitieren
APA
Faraj, K. S., Oerline, M., Kaufman, S. R., Dall, C., Srivastava, A., Caram, M. E. V., Shahinian, V. B., & Hollenbeck, B. K. (2024). Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae155
Vancouver
Faraj KS, Oerline M, Kaufman SR, Dall C, Srivastava A, Caram MEV, et al. Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae155
BibTeX
@article{Faraj2024,
author = {Faraj, Kassem S and Oerline, Mary and Kaufman, Samuel R and Dall, Christopher and Srivastava, Arnav and Caram, Megan E V and Shahinian, Vahakn B and Hollenbeck, Brent K},
title = {Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae155}
}
EUVIMED